AU2005256468B2 - Novel use of peptide compounds for treating essential tremor and other tremor syndromes - Google Patents

Novel use of peptide compounds for treating essential tremor and other tremor syndromes Download PDF

Info

Publication number
AU2005256468B2
AU2005256468B2 AU2005256468A AU2005256468A AU2005256468B2 AU 2005256468 B2 AU2005256468 B2 AU 2005256468B2 AU 2005256468 A AU2005256468 A AU 2005256468A AU 2005256468 A AU2005256468 A AU 2005256468A AU 2005256468 B2 AU2005256468 B2 AU 2005256468B2
Authority
AU
Australia
Prior art keywords
tremor
use according
compound
treatment
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005256468A
Other languages
English (en)
Other versions
AU2005256468A1 (en
Inventor
Thomas Stohr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
UCB Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Pharma GmbH filed Critical UCB Pharma GmbH
Publication of AU2005256468A1 publication Critical patent/AU2005256468A1/en
Assigned to UCB PHARMA GMBH reassignment UCB PHARMA GMBH Alteration of Name(s) of Applicant(s) under S113 Assignors: SCHWARZ PHARMA AG
Application granted granted Critical
Publication of AU2005256468B2 publication Critical patent/AU2005256468B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2005256468A 2004-06-24 2005-06-22 Novel use of peptide compounds for treating essential tremor and other tremor syndromes Ceased AU2005256468B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24
US60/582,084 2004-06-24
PCT/EP2005/006750 WO2006000397A1 (en) 2004-06-24 2005-06-22 Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Publications (2)

Publication Number Publication Date
AU2005256468A1 AU2005256468A1 (en) 2006-01-05
AU2005256468B2 true AU2005256468B2 (en) 2010-12-09

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005256468A Ceased AU2005256468B2 (en) 2004-06-24 2005-06-22 Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Country Status (19)

Country Link
US (1) US7427601B2 (enExample)
EP (1) EP1758606A1 (enExample)
JP (1) JP5038892B2 (enExample)
KR (1) KR20070034477A (enExample)
CN (1) CN1964733B (enExample)
AR (1) AR049940A1 (enExample)
AU (1) AU2005256468B2 (enExample)
BR (1) BRPI0512622A (enExample)
CA (1) CA2566301C (enExample)
EA (1) EA013592B1 (enExample)
IL (1) IL179732A0 (enExample)
MX (1) MXPA06015010A (enExample)
MY (1) MY146509A (enExample)
NO (1) NO20070423L (enExample)
NZ (1) NZ551207A (enExample)
TW (1) TWI361693B (enExample)
UA (1) UA88166C2 (enExample)
WO (1) WO2006000397A1 (enExample)
ZA (1) ZA200609021B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2008070994A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
WO2012084126A2 (en) 2010-12-02 2012-06-28 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20180042903A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
WO2000051586A2 (en) * 1999-03-01 2000-09-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound
WO2002013766A2 (en) * 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Valproic acid derivatives for the treatment of pain
WO2002015922A2 (en) * 2000-08-25 2002-02-28 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
WO2002074297A1 (en) * 2001-03-21 2002-09-26 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US7112612B2 (en) 2000-11-21 2006-09-26 Ucb S.A. N-alkylated GABA compounds, processes for their preparation and their use as medicaments
WO2002067931A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
PT1243262E (pt) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
EP1539145A2 (en) * 2002-09-13 2005-06-15 Eisai Co., Ltd. Method of treating tremors
DE60318749T2 (de) 2002-11-18 2009-01-22 Bioprospecting Nb Inc. Paralytisches peptid von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
WO2000051586A2 (en) * 1999-03-01 2000-09-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound
WO2002013766A2 (en) * 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Valproic acid derivatives for the treatment of pain
WO2002015922A2 (en) * 2000-08-25 2002-02-28 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
US20020086828A1 (en) * 2000-08-25 2002-07-04 Harris Robert H. Uses for amino acid anticonvulsants
WO2002074297A1 (en) * 2001-03-21 2002-09-26 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOVINGA C A: "SPM-927" Idrugs, Current Drugs Ltd, GB, vol. 6, no. 5, May 2003, pages 479-485 *
MCLEANE G et al: Neuroscience Letters, Limerick, IE, vol. 352, no. 2, 4 December 2003, pages 117-120 *

Also Published As

Publication number Publication date
TW200603823A (en) 2006-02-01
JP2008503533A (ja) 2008-02-07
AR049940A1 (es) 2006-09-13
AU2005256468A1 (en) 2006-01-05
MXPA06015010A (es) 2007-03-26
NO20070423L (no) 2007-03-22
WO2006000397A1 (en) 2006-01-05
NZ551207A (en) 2010-07-30
EP1758606A1 (en) 2007-03-07
CA2566301A1 (en) 2006-01-05
UA88166C2 (ru) 2009-09-25
CN1964733B (zh) 2012-05-23
KR20070034477A (ko) 2007-03-28
CA2566301C (en) 2011-06-14
IL179732A0 (en) 2007-05-15
CN1964733A (zh) 2007-05-16
EA200700108A1 (ru) 2007-06-29
EA013592B1 (ru) 2010-06-30
JP5038892B2 (ja) 2012-10-03
TWI361693B (en) 2012-04-11
MY146509A (en) 2012-08-15
BRPI0512622A (pt) 2008-03-25
ZA200609021B (en) 2008-04-30
US7427601B2 (en) 2008-09-23
US20050288234A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
AU2005256468B2 (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
US7718161B2 (en) Method for treating a motoneuron disorder
CA2565051C (en) Novel use of peptide compounds for treating dyskinesia
US6803481B2 (en) Use of peptide class of compound for treating non neuropathic inflammatory pain
AU2005226928B2 (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
EP1754476A1 (en) Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
AU2005251465B2 (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia
AU2005232395B2 (en) Use of peptidic compounds for the prophylaxis and treatment of chronic headache
AU2002257681A1 (en) Novel use of a peptide class of compound for treating non neuropathic inflammatory pain
CN100562312C (zh) 肽化合物用于治疗运动障碍的新用途
HK1049960A (en) Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
HK1079462A (en) Novel use of peptide compounds for treating dyskinesia
KR20070018067A (ko) 삼차 신경통의 통증을 치료하기 위한 펩티드 화합물의신규한 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired